-transparent.png){kind=logo}
The possible competition of isoniazid for the acetylation of sulphadimidine was studied by comparing the degree of acetylation of urine sulphadimidine (1 g orally) in isoniazid-treated and in isoniazid-untreated patients. The former group (isoniazid 300 mg once daily) consisted of 5 slow and 5 rapid acetylators and the latter group of 5 and 6 respective acetylator phenotypes. In all of the 4-8, 8-12 and 12-24 h urine fractions, the acetylation percentage of sulphadimidine and its distribution pattern were practically unaffected by the isoniazid. This suggests that isoniazid therapy does not interfere significantly with the routine acetylator phenotyping by means of sulphadimidine.
P Ylitalo, and
L Auterinen, and
A Marttinen, and
T Koivula
June 1972,
Canadian Medical Association journal,
P Ylitalo, and
L Auterinen, and
A Marttinen, and
T Koivula
June 1972,
Canadian Medical Association journal,
P Ylitalo, and
L Auterinen, and
A Marttinen, and
T Koivula
February 1977,
British journal of clinical pharmacology,
P Ylitalo, and
L Auterinen, and
A Marttinen, and
T Koivula
August 1991,
Japanese journal of pharmacology,
P Ylitalo, and
L Auterinen, and
A Marttinen, and
T Koivula
January 1981,
Acta medica Scandinavica,
P Ylitalo, and
L Auterinen, and
A Marttinen, and
T Koivula
January 1973,
The African journal of medical sciences,
P Ylitalo, and
L Auterinen, and
A Marttinen, and
T Koivula
January 1986,
European journal of clinical pharmacology,
P Ylitalo, and
L Auterinen, and
A Marttinen, and
T Koivula
January 1996,
The Indian journal of chest diseases & allied sciences,
P Ylitalo, and
L Auterinen, and
A Marttinen, and
T Koivula
January 1981,
European journal of clinical pharmacology,
P Ylitalo, and
L Auterinen, and
A Marttinen, and
T Koivula
December 1984,
International journal of clinical pharmacology, therapy, and toxicology,
